544 related articles for article (PubMed ID: 34983696)
1. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.
Jablonka S; Hennlein L; Sendtner M
Neurol Res Pract; 2022 Jan; 4(1):2. PubMed ID: 34983696
[TBL] [Abstract][Full Text] [Related]
2. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.
Singh RN; Ottesen EW; Singh NN
Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185
[TBL] [Abstract][Full Text] [Related]
3. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
Aslesh T; Yokota T
Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of Spinal Muscular Atrophy].
Ishiyama A
Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.
Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA
Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193
[TBL] [Abstract][Full Text] [Related]
7. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1.
Costamagna G; Govoni A; Wise A; Corti S
Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109
[TBL] [Abstract][Full Text] [Related]
8. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.
Chiriboga CA
Paediatr Drugs; 2022 Nov; 24(6):585-602. PubMed ID: 36028610
[TBL] [Abstract][Full Text] [Related]
10. Modern approaches in gene therapy of motor neuron diseases.
Zakharova M
Med Res Rev; 2021 Sep; 41(5):2634-2655. PubMed ID: 32638429
[TBL] [Abstract][Full Text] [Related]
11. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
Li Y; Zeng H; Wei Y; Ma X; He Z
Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
[TBL] [Abstract][Full Text] [Related]
12. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
Hjartarson HT; Nathorst-Böös K; Sejersen T
Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
[TBL] [Abstract][Full Text] [Related]
13. Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy.
Bagga P; Singh S; Ram G; Kapil S; Singh A
Front Neurol; 2024; 15():1368658. PubMed ID: 38854961
[TBL] [Abstract][Full Text] [Related]
14. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.
Messina S; Sframeli M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32668756
[TBL] [Abstract][Full Text] [Related]
15. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
Markati T; Fisher G; Ramdas S; Servais L
Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Adult Spinal Muscular Atrophy: Overview and Recent Developments.
Brakemeier S; Stolte B; Kleinschnitz C; Hagenacker T
Curr Pharm Des; 2022; 28(11):892-898. PubMed ID: 35352647
[TBL] [Abstract][Full Text] [Related]
17. Selecting disease-modifying medications in 5q spinal muscular atrophy.
Cartwright MS; Upadhya S
Muscle Nerve; 2021 Oct; 64(4):404-412. PubMed ID: 34231920
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy.
Kotulska K; Fattal-Valevski A; Haberlova J
Front Neurol; 2021; 12():726468. PubMed ID: 34721262
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I.
Mirea A; Shelby ES; Axente M; Badina M; Padure L; Leanca M; Dima V; Sporea C
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884240
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
